

CLAIM AMENDMENTS

1. cancelled

2. cancelled

3. (currently amended) A method of treating or preventing a peroxisome proliferation-activated α -receptor-related PPAR α -related disease comprising:

administering an effective amount of a pharmaceutical composition comprising a PPAR α agonist and a suitable excipient to an individual in need of such treatment.

4. (currently amended) The method according to claim 3 wherein the peroxisome proliferation-activated α -receptor-related PPAR α -related disease is selected from the group comprising: restenosis, chronic renal failure, atherosclerosis, hypertension, diabetes, benign hyperplastic prostate, prostate cancer, rheumatoid arthritis, asthma, stress-induced inflammation, hypoxia, fibrotic disease, skin wound healing, keloids, Crohn's disease, ulcerative colitis, endometriosis, fibromatosis, pulmonary hypertension, cardiac hypertrophy, congestive heart failure and leiomyomas (fibroids).

5. cancelled.

6. cancelled.